B細胞悪性腫瘍の成人参加者の有害事象、疾患活動性の変化、および経口ABBV-101が体内をどのように移動するかを評価するための研究
B細胞悪性腫瘍の参加者におけるBTK分解剤、ABBV-101の安全性、薬物動態、および予備的有効性を評価するための最初のヒト研究
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin's lymphomas: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma (DLBCL), non-germinal center B cell (GCB) DLBCL, mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), or transformed indolent NHL. Adverse events will be assessed.
ABBV-101 is an investigational drug being developed for the treatment of NHL. This study is a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-101. Approximately 200 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide.
Participants will receive escalating oral doses of ABBV-101, until the MAD/MTD is determined, as part of the approximately 88 month study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Arizona
-
Tucson、Arizona、アメリカ、85711
- Arizona Oncology - Tucson - Wilmot Road /ID# 252351
-
-
California
-
Orange、California、アメリカ、92868-3201
- UC Irvine Medical Center /ID# 263020
-
Palo Alto、California、アメリカ、94304
- Stanford University - Palo Alto /ID# 249683
-
-
Colorado
-
Aurora、Colorado、アメリカ、80012
- Rocky Mountain Cancer Centers - Aurora /ID# 252237
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 249347
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215-5400
- Beth Israel Deaconess Medical Center /ID# 249302
-
-
New Jersey
-
New Brunswick、New Jersey、アメリカ、08901
- Rutgers Cancer Institute of New Jersey /ID# 249323
-
-
New York
-
Albany、New York、アメリカ、12206-5013
- New York Oncology Hematology - Albany Cancer Center /ID# 252240
-
Lake Success、New York、アメリカ、11042
- Northwell Health - Monter Cancer Center /ID# 250422
-
Rochester、New York、アメリカ、14642-0001
- University of Rochester Medical Center /ID# 249324
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45267-2827
- University of Cincinnati /ID# 249299
-
-
Oregon
-
Eugene、Oregon、アメリカ、97401-6036
- Oncology Assoc. of Oregon PC - WVCI and Research Ctr - Springfield /ID# 249309
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 250341
-
-
Texas
-
Houston、Texas、アメリカ、77030
- MD Anderson Cancer Center /ID# 249293
-
-
-
-
Cambridgeshire
-
Cambridge、Cambridgeshire、イギリス、CB2 2QQ
- Addenbrookes Hospital /ID# 256242
-
-
England
-
Leicester、England、イギリス、LE1 5WW
- Leicester Royal Infirmary /ID# 255171
-
-
Greater London
-
London、Greater London、イギリス、SE5 9RS
- Kings College Hospital NHS Foundation Trust /ID# 253670
-
London、Greater London、イギリス、NW1 2BU
- UCLH NHS FT - University College Hospital /ID# 260202
-
-
-
-
Central District
-
Tsrifin、Central District、イスラエル、70300
- Yitzhak Shamir Medical Center /ID# 254566
-
-
Jerusalem
-
Jerusalem、Jerusalem、イスラエル、91120
- Hadassah Medical Center-Hebrew University /ID# 251123
-
-
Tel Aviv
-
Ramat Gan、Tel Aviv、イスラエル、5265601
- The Chaim Sheba Medical Center /ID# 251122
-
Tel Aviv、Tel Aviv、イスラエル、6423906
- Tel Aviv Sourasky Medical Center /ID# 259608
-
-
-
-
-
Bergamo、イタリア、24127
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII /ID# 260317
-
Bologna、イタリア、40138
- IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 255172
-
-
Milano
-
Milan、Milano、イタリア、20132
- IRCCS Ospedale San Raffaele /ID# 253531
-
Milan、Milano、イタリア、20162
- ASST Grande Ospedale Metropolitano Niguarda /ID# 253532
-
-
Piedmont
-
Turin、Piedmont、イタリア、10126
- A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 253530
-
-
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 2M9
- University Health Network_Princess Margaret Cancer Centre /ID# 253483
-
-
Quebec
-
Montreal、Quebec、カナダ、H2X 3E4
- Centre Hospitalier De L'Universite De Montreal - Hopital Saint-Luc /ID# 253428
-
-
-
-
-
Barcelona、スペイン、08035
- Hospital Universitario Vall de Hebron /ID# 260447
-
Madrid、スペイン、28034
- Hospital Universitario Ramon y Cajal /ID# 260450
-
Madrid、スペイン、28040
- Hospital Universitario Fundacion Jimenez Diaz /ID# 253654
-
Madrid、スペイン、28050
- Hospital Universitario HM Sanchinarro /ID# 253655
-
Salamanca、スペイン、37711
- Hospital Universitario de Salamanca /ID# 253656
-
-
Madrid
-
Majadahonda、Madrid、スペイン、28222
- Hospital Universitario Puerta de Hierro - Majadahonda /ID# 260196
-
-
-
-
-
Berlin、ドイツ、12203
- Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 257431
-
Hamburg、ドイツ、20246
- Universitaetsklinikum Hamburg-Eppendorf /ID# 264566
-
-
Baden-Wurttemberg
-
Ulm、Baden-Wurttemberg、ドイツ、89081
- Universitaetsklinikum Ulm /ID# 253742
-
-
Bavaria
-
Würzburg、Bavaria、ドイツ、97080
- Universitaetsklinikum Wuerzburg /ID# 254636
-
-
Mecklenburg-Vorpommern
-
Rostock、Mecklenburg-Vorpommern、ドイツ、18057
- Universitaetsmedizin Rostock /ID# 259657
-
-
Saarland
-
Homburg、Saarland、ドイツ、66424
- Universitaetsklinikum des Saarlandes /ID# 257435
-
-
-
-
-
Paris、フランス、75010
- Hopital Saint-Louis /ID# 253663
-
-
Gironde
-
Bordeaux、Gironde、フランス、33000
- Institut Bergonie /ID# 253664
-
-
Herault
-
Montpellier、Herault、フランス、34295
- CHU Montpellier - Hopital Saint Eloi /ID# 253666
-
-
Nord
-
Lille、Nord、フランス、59037
- CHRU Lille - Hopital Claude Huriez /ID# 253665
-
-
Pays de la Loire Region
-
Nantes、Pays de la Loire Region、フランス、44000
- Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 256248
-
-
Val-de-Marne
-
Villejuif、Val-de-Marne、フランス、94805
- Institut Gustave Roussy /ID# 253662
-
-
-
-
Chiba
-
Kashiwa-shi、Chiba、日本、277-8577
- National Cancer Center Hospital East /ID# 250684
-
-
Kyoto
-
Kyoto、Kyoto、日本、606-8507
- Kyoto University Hospital /ID# 261837
-
-
Tokyo
-
Chuo-ku、Tokyo、日本、104-0045
- National Cancer Center Hospital /ID# 250680
-
Koto-ku、Tokyo、日本、135-8550
- The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 260375
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
For Dose Escalation only (including backfill): Participants have received at least two prior systemic therapies, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), have measurable disease requiring treatment, and have a documented diagnosis for one of the following third line or later B-cell malignancies, from one of the following world health organization (WHO)-defined histologies (Swerdlow et al 2016):
-
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
- For Dose Escalation backfill only - Bruton's tyrosine kinase inhibitor (BTKi)/Bruton's tyrosine kinase degrader (BTKd)-naïve CLL/SLL. Participants with a documented diagnosis of CLL/SLL who have received at least one prior systemic therapy that cannot be a BTK inhibitor or degrader, and, with the exception of BTK pathway agents, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), and have measurable disease requiring treatment.
- For Dose Escalation backfill only - BTKi/BCL-2i combination regimen-exposed 2L CLL/SLL. Participants with a documented diagnosis of CLL/SLL who have received one prior systemic therapy with a BTKi and BCL-2i combination regimen, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), and have measurable disease requiring treatment.
-
Chimeric antigen receptor T-cells (CAR-T)/hematopoietic cell transplant (HCT) relapsed/refractory (R/R) or ineligible diffuse large b-cell lymphoma (DLBCL) from the following histologies: DLBCL not otherwise specified (NOS) (germinal center B cell [GCB] and non-GCB DLBCL), T-cell/histiocyte-rich large B-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, anaplastic lymphoma kinase positive (ALK+) large B-cell lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high-grade B-cell lymphoma NOS.
-
Mantle cell lymphoma (MCL)
-
Follicular lymphoma [FL] (grades 1-3b)
-
Marginal zone lymphoma [MZL] (splenic, extranodal, and nodal)
-
Waldenström macroglobulinemia (WM)
-
Transformed indolent non-Hodgkin's lymphoma (iNHL)
-
-
Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or 2. For EU only: Participant has an ECOG PS of 0 or 1.
-
Participant has a life expectancy >= 12 weeks.
-
Prior Bruton's tyrosine kinase inhibitor (BTKi) is allowed.
-
Adequate hematologic, renal, and hepatic function per the protocol.
Exclusion Criteria:
- Previously treated with a Bruton's tyrosine kinase (BTK) degrader, except ABBV-101.
- Known active central nervous system (CNS) disease, or primary CNS lymphoma. Participants with prior CNS disease that have been effectively treated may be eligible.
- Uncontrolled active systemic infection requiring systemic treatment that is ongoing or was completed <= 14 days before the first dose of study drug, or active cytomegalovirus infection.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Dose Escalation: ABBV-101
Participants with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) will receive escalating doses of ABBV-101, until the maximum administered dose (MAD)/Maximum tolerated dose (MTD) is determined, as part of the approximately 88 month study duration. |
Oral:Tablet |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants with Adverse Events (AE)
時間枠:Up to Approximately 88 Months
|
AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 88 Months
|
|
Change in Laboratory Parameters
時間枠:Up to Approximately 88 Months
|
Number of participants with clinically significant change from baseline in clinical laboratory test results like hematology will be reported. |
Up to Approximately 88 Months
|
|
Change in Vital Signs
時間枠:Up to Approximately 88 Months
|
Number of participants with clinically significant change from baseline in vital signs like systolic and diastolic blood pressure will be reported. |
Up to Approximately 88 Months
|
|
Change in Electrocardiogram (ECG)
時間枠:Up to Approximately 88 Months
|
12-lead resting ECGs will be recorded. Parameters include RR interval, PR interval, QT interval, and QRS duration. |
Up to Approximately 88 Months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum Observed Serum Concentration (Cmax) of ABBV-101
時間枠:Up to Approximately 88 Months
|
Maximum observed serum concentration of ABBV-101. |
Up to Approximately 88 Months
|
|
Time to Cmax (Tmax) of ABBV-101
時間枠:Up to Approximately 88 Months
|
Time to Cmax of ABBV-101. |
Up to Approximately 88 Months
|
|
Area Under the Serum Concentration Versus Time Curve (AUC) of ABBV-101
時間枠:Up to Approximately 88 Months
|
Area under the serum concentration versus time curve (AUC) of ABBV-101. |
Up to Approximately 88 Months
|
|
Number of Participants with Response of Partial Response (PR) or Better Response (Overall Response) per Disease-Specific Criteria
時間枠:Up to Approximately 88 Months
|
Number of participants with response of PR or better response (overall response) per disease-specific criteria. |
Up to Approximately 88 Months
|
|
Duration of Response (DOR)
時間枠:Up to Approximately 88 Months
|
DOR is defined for participants achieving PR or better as the time from the initial response per Investigator review to disease progression or death of any cause, whichever occurs earlier. |
Up to Approximately 88 Months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:ABBVIE INC.、AbbVie
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- M23-647
- 2023 (米国 NIH グラント/契約)
- 2023-503594-38-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。